In addition, the first‐line medicine for type 2 diabetes, metformin, which degrades PD‐L1 protein level and improves the effects of CTLA‐4 blockade, successfully suppressed tumor growth in vitro and in vivo137, 138. Here, CTLA4 is linked to neoplasm.